新聞稿

 

REVIVE-HF seeks to demonstrate superiority of the Revivent TC System to current guideline treatment for heart failure

SAN RAMON, Calif.--()--BioVentrix, Inc., developer of the first transcatheter device for left ventricular remodeling after a heart attack, today announced that Ralph Stephan von Bardeleben, MD, of the University Medical Center of Mainz (Germany) has joined the European REVIVE-HF clinical trial of the Revivent TC™ Transcatheter Ventricular Enhancement System as co-principal investigator.


SAN RAMON, Calif. –  February 18, 2020 – BioVentrix, Inc., a pioneer of technologies and procedures for the less invasive treatment of heart failure (HF), today announced that Gregg Stone, MD, of New York’s Mount Sinai Health System has signed on to the pivotal ALIVE Trial of the Revivent TC™ TransCatheter Ventricular Enhancement System as co-principal investigator.


San Ramon, CA – February 6, 2020 – Bioventrix, Inc., developer of the first transcatheter device for left ventricular remodeling after a heart attack, today announced it received renewal of the highest priority reimbursement in Germany for the Revivent TC™ TransCatheter Ventricular Enhancement System by achieving the NUB Status 1 designation from InEk, the German Institute for Hospital Remuneration.


Image

BioVentrix是一家私營醫療器械公司,總部位於美國加利福尼亞州聖拉蒙。

我們的新聞

聯繫我們

© 2020 BioVentrix。版權所有。由Medtech MomentumMedTech Momentum提供技術支持
Revivent TC™商標是BioVentrix擁有的聯邦註冊商標。明確禁止任何未經授權的使用。